Six weeks after receiving their first samples of the A/H1N1 swine flu virus, two China biotechs have begun clinical trials of vaccines for the potentially fatal version of flu. Sinovac Biotech and Hualan Biological Engineering will each test their vaccines in about 2,000 volunteers, a process that will take about two months. Both companies say they expect to announce results in September. More details...

Stock Symbol: (NYSE Amex: SVA)